



FOR IMMEDIATE RELEASE

MAJOR MILESTONE ACHIEVEMENT IN AN ASSOCIATED COMPANY

Hong Kong, 6 February 2012- The directors of Lee's Pharmaceutical Holdings Limited ("the Group") are pleased to announce that Powder Pharmaceutical Incorporated ("PPI"), an associated company of the Group, has achieved a major milestone in December 2011. The first manufacturing qualification run for the production of Zingo™ in the new Hong Kong manufacturing facility has been completed. Followed by sufficient stability data, PPI will file for site approval with the U.S. FDA in the second quarter of 2012. Zingo™ is an FDA approved, needle-less, painless, fast, lidocaine powder injection system that provides local analgesia for children age 3 and over as well as adults prior to IV/cannula placements.

The Group has 15.36% interest in the share capital of PPI.

About Zingo™

Zingo™ is the first needle less, painless powder injection system to be approved for analgesia at an IV/cannula access site. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain free needle access procedure. Zingo™ is approved for use in children over 3 years of age and adults. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo™ versus a placebo system.

Powder Pharmaceuticals Inc. is a privately held company based in Hong Kong that is developing products that utilize a proprietary needle less, painless, powder delivery technology. Powder Pharmaceuticals intends to supply Zingo™ globally through international business partners.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 18 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S., Japanese and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharma is available on the internet at www.leespharm.com.



FOR IMMEDIATE RELEASE

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results.